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Abstract:
About 1.6 million Americans suffer from Inflammatory Bowel Disease 
(IBD), a condition that includes Crohn’s Disease and Ulcerative Colitis 
(2). Treatment of this condition focuses on reducing the inflammation 
caused by IBD either through anti inflammatory drugs or 
immunosuppressants (4). Many times it is preferable to deliver these 
drugs topically,  and foams provide several benefits over the common 
liquid enemas (as noted in Malchow 2002)(3), Furthermore, several 
foam products are already on the market to treat colitis including 
foams containing Mesalazine and Budesonide (1). Our experiment 
focuses on formulating an optimal foaming solution for lower 
gastrointestinal tract drug delivery. In addition to clinical treatment, 
we hope these foams will help researchers test new therapies for  IBD 
and other disorders affecting the lower digestive system.
Background: 
Drug delivery, to the gastrointestinal tract poses many unique problems. 
Topical delivery enemas minimizes systemic exposure and increases drug 
effectiveness. however they presents other problems including retention 
and patient compliance (4)(3). Foam enemas overcome some of these 
problems and have been shown to be as effective as their liquid 
counterparts (3). Still foams have their own problems. One challenge is 
choosing a surfactant that will not irritate IBD (5).  Many synthetic 
surfactants are irritants, and studies have shown that common surfactants 
may cause colitis in mice (6).  Many times foam enemas use smaller 
concentrations of  nonionic surfactants which are less irritating(5). Still the 
situation is less than ideal both for patient comfort and for the condition 
itself. The other large concern is the density of the foam and drug holding 
capacity of the foaming solution (5)(7). In this experiment we attempted 
to overcome all three of these concerns using two alternative foaming 
agents; sodium caseinate, and l-a-phosphatidylcholine. By maximizing 
their foam half-life, foamability, drainage, and density, we hope to 
evaluate their use as a drug delivery method for IBD.
Methodology: 
We made solutions of Polyethylene Glycol (PEG) or Alginic Acid 
(Alginate), and a foaming agent (pluronic, sodium caseinate, or l-α-
phosphatidylcholine) and tested the following characteristics.
Half Life: We tested the stability of the foam by measuring the “half 
life” of a column of foam produced by bubbling compressed air at 
1lpm through 10 ml of the solution in a 1½” chromatography column 
with a fritted glass filter in the base. After generation, the foam height 
was marked. A video camera was used to record the time it took for 
the foam to degrade to half of its original height.
Foamability: Using the same system we tested the volume of foam 
each solution was capable of generating. In separate trials the solution 
was allowed to foam until an air pocket formed in the bottom of the 
column. After waiting a minute the length of the foam was measured 
and a volume was calculated.
Drainage: To test drainage rate of the foam we completely foamed a 
10 ml sample of the solution as described in the foamability test. This 
column was immediately inverted and allowed to drain into a 10ml 
graduated cylinder. Volume readings were taken every minute for ten 
minutes.
Density: We tested density along with the drainage test. After one 
minute, we measured the foam height and calculated the volume. 
Next we massed the drained solution and calculated the mass of 
solution still in the foam. Using these measurements we calculated the 
density of the foam.
*Research was funded in part by Iowa State University Foundation
Results:
This project is still very much a work in progress. Initially we didn’t know 
that synthetic surfactants would irritate IBD, and we ran many test with 
pluronic. You can see these results in middle charts. These trials taught us 
a lot about the procedure and the foaming properties of solutions. Firstly 
we learned that higher concentrations of PEG and Alginate and 
surfactant did not necessarily  produce longer lasting foams. We also saw 
that the foams could vary widely in their size and composition, a fact that 
led us to measure the extra parameters in the new trials. Finally, and 
perhaps most importantly it showed us that the surfactant concentration 
was the most important factor in the foam half life. Concentration of the 
PEG or Alginate played an important role, but surfactant concentration 
widely  separated the different solutions. From this observation we 
decided to fix the concentration of these reagents to an value of 1.5% 
and focus on foaming agent concentration for the first part of this 
experiment. You can see our preliminary trials in the table below.
Future Direction:
Once we finish these trials and find the optimal foaming solution, there are 
many ways we can extend this project. For example, we can test how 
loading the foam with different active agents affects density and stability. 
We are especially interested in testing this foam for it’s ability to deliver 
nanoparticles. 
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Substance
Foaming 
Agent 1
% 
wt.
Foaming 
Agent 2
% 
wt.
1/2 life 
(min) Comments
PEG l-a-P 0.1 -
Alginate l-a-P 0.1 - The foam was stable, but the bubbles were to large and thin to do any good
PEG Caseinate 1
Alginate Caseinate 1 170
PEG l-a-P 1 -
It seems like the phosphatidylcholine only stabilizes the foam and does not help its 
foamability
Alginate l-a-P 1 24 + hrs
by this time most of the liquid had drained out. Additionaly after the foam collapsed some 
of the l-a came out of solution
PEG l-a-P 1Caseinate 0.5 32
Again, something came out of solution after foaming. It seems like the l-a may have a 
minimal stabilizing effect at these concentrations
PEG Caseinate 0.5 30
Alginate Caseinate 0.5 219 Non constant rate of collapse
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